{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:02:53Z","timestamp":1787061773910,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62376050"],"award-info":[{"award-number":["62376050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]},{"name":"the Science and Technology Bureau of Dalian","award":["2022RQ088"],"award-info":[{"award-number":["2022RQ088"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-20739-7","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:28:09Z","timestamp":1761038889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world safety assessment of tamsulosin based on adverse event analysis from the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Zufa","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengze","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"2","key":"20739_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00002512-200219020-00004","volume":"19","author":"CJ Dunn","year":"2002","unstructured":"Dunn, C. J., Matheson, A. & Faulds, D. M. Tamsulosin: a review of its Pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 19 (2), 135\u2013161 (2002).","journal-title":"Drugs Aging"},{"issue":"4","key":"20739_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.21037\/tau.2019.07.02","volume":"8","author":"BR Kava","year":"2019","unstructured":"Kava, B. R., Verbeek, A. E., Wruck, J. M. & Gittelman, M. Tamsulosin dispensation patterns in the united states: a real-world, longitudinal, population claims database analysis. Translational Androl. Urol. 8 (4), 329\u2013338 (2019).","journal-title":"Translational Androl. Urol."},{"issue":"6","key":"20739_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke, C. et al. EAU guidelines on the assessment of Non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 67 (6), 1099\u20131109 (2015).","journal-title":"Eur. Urol."},{"issue":"5","key":"20739_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.5489\/cuaj.10124","volume":"4","author":"JC Nickel","year":"2010","unstructured":"Nickel, J. C., M\u00e9ndez-Probst, C. E., Whelan, T. F., Paterson, R. F. & Razvi, H. 2010 update: guidelines for the management of benign prostatic hyperplasia. Can. Urol. Association J. = J. De l\u2019Association Des. Urologues Du Can. 4 (5), 310\u2013316 (2010).","journal-title":"Can. Urol. Association J. = J. De l\u2019Association Des. Urologues Du Can."},{"issue":"2","key":"20739_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pop.2019.02.003","volume":"46","author":"RC Langan","year":"2019","unstructured":"Langan, R. C. Benign prostatic hyperplasia. Prim. Care. 46 (2), 223\u2013232 (2019).","journal-title":"Prim. Care"},{"issue":"8","key":"20739_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamainternmed.2018.2259","volume":"178","author":"AC Meltzer","year":"2018","unstructured":"Meltzer, A. C. et al. Effect of Tamsulosin on passage of symptomatic ureteral stones: A randomized clinical trial. JAMA Intern. Med. 178 (8), 1051\u20131057 (2018).","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"20739_CR7","doi-asserted-by":"publisher","first-page":"11116","DOI":"10.1038\/s41598-024-61977-5","volume":"14","author":"BT Yoosuf","year":"2024","unstructured":"Yoosuf, B. T. et al. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci. Rep. 14 (1), 11116 (2024).","journal-title":"Sci. Rep."},{"issue":"4","key":"20739_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0022-5347(05)65769-2","volume":"166","author":"CC Schulman","year":"2001","unstructured":"Schulman, C. C. et al. Long-term use of Tamsulosin to treat lower urinary tract symptoms\/benign prostatic hyperplasia. J. Urol. 166 (4), 1358\u20131363 (2001).","journal-title":"J. Urol."},{"key":"20739_CR9","first-page":"f6320","volume":"347","author":"ST Bird","year":"2013","unstructured":"Bird, S. T. et al. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40\u201385 years in the united states: risk window analyses using between and within patient methodology. BMJ (Clinical Res. ed). 347, f6320 (2013).","journal-title":"BMJ (Clinical Res. ed)"},{"issue":"3","key":"20739_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/pds.4361","volume":"27","author":"Y Duan","year":"2018","unstructured":"Duan, Y., Grady, J. J., Albertsen, P. C. & Helen Wu, Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol. Drug Saf. 27 (3), 340\u2013348 (2018).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"20739_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","volume":"12","author":"S Cirmi","year":"2020","unstructured":"Cirmi, S., El Abd, A., Letinier, L., Navarra, M. & Salvo, F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS). Cancers 12(4), 826 (2020).","journal-title":"Cancers"},{"issue":"7","key":"20739_CR12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10 (7), 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"20739_CR13","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou, F. et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front. Pharmacol. 15, 1338902 (2024).","journal-title":"Front. Pharmacol."},{"issue":"12","key":"20739_CR14","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1111\/bcp.15460","volume":"88","author":"C Ji","year":"2022","unstructured":"Ji, C., Bai, J., Zhou, J., Zou, Y. & Yu, M. Adverse event profiles of PCSK9 inhibitors Alirocumab and evolocumab: data mining of the FDA adverse event reporting system. Br. J. Clin. Pharmacol. 88 (12), 5317\u20135325 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"20739_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown, E. G. Using meddra: implications for risk management. Drug Saf. 27 (8), 591\u2013602 (2004).","journal-title":"Drug Saf."},{"issue":"4","key":"20739_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","volume":"41","author":"A Verden","year":"2018","unstructured":"Verden, A., Dimbil, M., Kyle, R., Overstreet, B. & Hoffman, K. B. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 41 (4), 357\u2013361 (2018).","journal-title":"Drug Saf."},{"issue":"6","key":"20739_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10 (6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"20739_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11 (1), 3\u201310 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"20739_CR19","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin, Y., Shu, Y., Zhu, J., Li, F. & Li, J. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib. Sci. Rep. 12 (1), 19555 (2022).","journal-title":"Sci. Rep."},{"issue":"3","key":"20739_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00210-022-02343-y","volume":"396","author":"B Gao","year":"2023","unstructured":"Gao, B., Zhang, D., Wang, Y., Wang, Z. & Wang, Z. The effect of Tamsulosin in postoperative urinary retention: a meta-analysis of randomized controlled trials. Naunyn. Schmiedebergs Arch. Pharmacol. 396 (3), 441\u2013451 (2023).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"issue":"12","key":"20739_CR21","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/medicina58121794","volume":"58","author":"HD Jung","year":"2022","unstructured":"Jung, H. D. et al. Silodosin versus tamsulosin for medical expulsive therapy of ureteral stones: an updated systematic review and meta-analysis of randomized controlled trials. Medicina (Kaunas Lithuania) 58(12), 1794 (2022).","journal-title":"Medicina (Kaunas Lithuania)"},{"issue":"5","key":"20739_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0149-2918(01)80022-9","volume":"23","author":"E Chrischilles","year":"2001","unstructured":"Chrischilles, E. et al. Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin. Ther. 23 (5), 727\u2013743 (2001).","journal-title":"Clin. Ther."},{"issue":"2","key":"20739_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eursup.2004.11.005","volume":"4","author":"MC Michel","year":"2005","unstructured":"Michel, M. C. et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of Tamsulosin compared to the modified release (MR) formulation. Eur. Urol. Supplements. 4 (2), 53\u201360 (2005).","journal-title":"Eur. Urol. Supplements"},{"issue":"4","key":"20739_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/19396360902833235","volume":"55","author":"Z Dong","year":"2009","unstructured":"Dong, Z. et al. Tamsulosin versus Terazosin for benign prostatic hyperplasia: a systematic review. Syst. Biology Reproductive Med. 55 (4), 129\u2013136 (2009).","journal-title":"Syst. Biology Reproductive Med."},{"issue":"3","key":"20739_CR25","first-page":"173","volume":"66","author":"S Milicevic","year":"2012","unstructured":"Milicevic, S. & Bijelic, R. Efficacy and safety of Tamsulosin in the treatment of benign prostatic hyperplasia. Med. Archives (Sarajevo Bosnia Herzegovina). 66 (3), 173\u2013176 (2012).","journal-title":"Med. Archives (Sarajevo Bosnia Herzegovina)"},{"issue":"6","key":"20739_CR26","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1464-410X.2011.10124.x","volume":"107","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn, C. G. et al. Clinical outcomes after combined therapy with dutasteride plus Tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of avodart and Tamsulosin (CombAT) trial. BJU Int. 107 (6), 946\u2013954 (2011).","journal-title":"BJU Int."},{"issue":"10","key":"20739_CR27","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1742-1241.2006.01107.x","volume":"60","author":"AC Pompeo","year":"2006","unstructured":"Pompeo, A. C. et al. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release Doxazosin and Tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. Int. J. Clin. Pract. 60 (10), 1172\u20131177 (2006).","journal-title":"Int. J. Clin. Pract."},{"issue":"5","key":"20739_CR28","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","volume":"185","author":"KT McVary","year":"2011","unstructured":"McVary, K. T. et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol. 185 (5), 1793\u20131803 (2011).","journal-title":"J. Urol."},{"issue":"10","key":"20739_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11934-021-01066-6","volume":"22","author":"K Gillams","year":"2021","unstructured":"Gillams, K., Julieb\u00f8-Jones, P., Julieb\u00f8, S. & Somani, B. K. Gender differences in kidney stone disease (KSD): findings from a systematic review. Curr. Urol. Rep. 22 (10), 50 (2021).","journal-title":"Curr. Urol. Rep."},{"issue":"2","key":"20739_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ucl.2021.12.003","volume":"49","author":"A Plochocki","year":"2022","unstructured":"Plochocki, A. & King, B. Medical treatment of benign prostatic hyperplasia. Urologic. Clin. North. Am. 49 (2), 231\u2013238 (2022).","journal-title":"Urologic. Clin. North. Am."},{"issue":"1","key":"20739_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00003495-200262010-00006","volume":"62","author":"KA Lyseng-Williamson","year":"2002","unstructured":"Lyseng-Williamson, K. A., Jarvis, B. & Wagstaff, A. J. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 62 (1), 135\u2013167 (2002).","journal-title":"Drugs"},{"issue":"9","key":"20739_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40264-018-0674-y","volume":"41","author":"SA Kaplan","year":"2018","unstructured":"Kaplan, S. A. & Chughtai, B. I. Safety of tamsulosin: A systematic review of randomized trials with a focus on women and children. Drug Saf. 41 (9), 835\u2013842 (2018).","journal-title":"Drug Saf."},{"issue":"1","key":"20739_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1291\/hypres.19.43","volume":"19","author":"T Ishimitsu","year":"1996","unstructured":"Ishimitsu, T. et al. Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Hypertens. Research: Official J. Japanese Soc. Hypertens. 19 (1), 43\u201349 (1996).","journal-title":"Hypertens. Research: Official J. Japanese Soc. Hypertens."},{"key":"20739_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5398","author":"B Welk","year":"2015","unstructured":"Welk, B. et al. The risk of fall and fracture with the initiation of a prostate-selective \u03b1 antagonist: a population based cohort study. BMJ https:\/\/doi.org\/10.1136\/bmj.h5398 (2015).","journal-title":"BMJ"},{"issue":"10","key":"20739_CR35","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/pds.5503","volume":"31","author":"L Latvala","year":"2022","unstructured":"Latvala, L., Tiihonen, M., Murtola, T. J., Hartikainen, S. & Tolppanen, A. M. Use of \u03b11-adrenoceptor antagonists Tamsulosin and Alfuzosin and the risk of alzheimer\u2019s disease. Pharmacoepidemiol. Drug Saf. 31 (10), 1110\u20131120 (2022).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"20739_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","volume":"23","author":"RS McIntyre","year":"2024","unstructured":"McIntyre, R. S., Mansur, R. B., Rosenblat, J. D. & Kwan, A. T. H. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the food and drug administration adverse event reporting system (FAERS). Exp. Opin. Drug Saf. 23 (1), 47\u201355 (2024).","journal-title":"Exp. Opin. Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20739-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20739-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20739-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:28:10Z","timestamp":1761038890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20739-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20739"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20739-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Our study did not require ethical approval as it did not involve human participants, animals, or any form of personal data collection. The research was based entirely on secondary data analysis from publicly available sources, which does not necessitate ethical review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"36726"}}